卡维地洛对慢性心力衰竭患者血清IL-6、TNF-α及运动耐量的影响被引量：1

下载PDF

导出

摘要目的:评价第三代非选择性β受体阻滞剂卡维地洛对慢性心力衰竭(CHF)血清中白介素-6(IL-6)、肿瘤坏死因子(TNF-)α水平及6min步行距离的影响。方法:将98例CHF患者分为常规抗心衰治疗组(48例)和在常规抗心衰治疗基础上加用卡维地洛组(50例),ELISA法测定所有CHF患者治疗前后血清IL-6、TNF-α水平,分析比较6min步行距离。结果:治疗前两组间各项指标比较差异无显著性(P>0.05);治疗6个月后,常规治疗组治疗前后血清IL-6、TNF-α水平,6min步行距离差异无显著性,卡维地洛组各项指标治疗前后比较差异均有显著性(P<0.05);治疗后卡维地洛组优于常规治疗组(P<0.05)。结论:卡维地洛可降低血清IL-6、TNF-α水平,显著改善心脏功能,对CHF疗效显著。

作者帅锋利李义勇陈良海郑小红

机构地区双流县第一人民医院内二科双流县疾病控制中心泸州医学院附属医院心内科

出处《泸州医学院学报》 2006年第2期133-134,共2页 Journal of Luzhou Medical College

关键词慢性心力衰竭白细胞介素-6 肿瘤坏死因子卡维地洛

分类号 R541.6 [医药卫生—心血管疾病] R972 [医药卫生—药品]

引文网络
相关文献

参考文献4

1To rre AG,Kapadia S,Benedict C,et a1.Proin flam matory cytokine levels in patients with depressed left ventricular ejection fraction:a report from the studies of left ventricular dysfunction (SOLVD)[J].Am Coll Cardiol,1996 ;27:1202
2Suramth D,Prsbhu MD,Bysani PhD.et al.Adrenergic blockade in eveloping heart failure effects on myocardi inflammatory cytokines,nitric oxide and remodeling[J].Circulation,2000;101:2103.
3胡琴,耿邵华,李隆贵.卡维地洛心肌保护作用的理论基础[J].心血管病学进展,2003,24(2):107-110. 被引量：17
4Tatli E,Kurum T.A controlled study of the effects of carvedilol on clinical events,left ventricular function and proinflammatory cytokines levels in patients with dilated cardiomyopathy[J].Can J Cardiol,2005 Mar 15;21(4):344

二级参考文献31

1[1]Sackner-Bemstein JD. Use of carvedilol in chronic heart failure: challenges in therapeutic management[ J ]. Prog Cardiovasc Dis, 1998,41 (suppl 1 ) :s53-s58.
2[2]Zweier JL. Measurement of superoxied derived free radicals inthe reperfused heart:Evidence Rui MV. Abreu, Dario JS. Santos,Antonio JM. Moreno for a free radical mechanism of reperfusion injury [J]. J Biol Chem, 1988,263: 1353-1357.
3[3]Cheng H Y, Randall CS, Holl WW, et al. Carvedilol-liposome interaction:evidence for strong association with the hydrophobic region of the lipid bilayers[J]. Biochem Biophys Acta, 1996,128:20-28.
4[4]Yue TL,Mckenna PJ,Gu JL,et al. Carvedilol,a new antihypertensive agent,prevents lipid peroxidation and oxidation injury to endothelial cells [J]. Hypertension, 1993,22:922-928.
5[5]Yue TL, Liu T, Feuerstein GZ. Carvedilol, a new bets adrenoceptor antagonist and vasodilator antihypoertensive drug, inhibits oxygen-radical-mediated lipid peroxidation in swine ventricular membranes [J]. Pharmacol Commun, 1992,1:27-35.
6[6]Yue TL,Wang X.Gu JL,et al. Carvedilol,a new vasodilating β-adrenoceptor anagonist, prevents low-density lipoprotein (LDL)-enhanced leukocyte adhesion to endothelial cells by inhibition of LDL oxidation [J]. Eur J Pharmacol, 1995,294:585-591.
7[7]Yue TL, Mckenna PJ, Ruffolo RR Jr,et al. Carvedilol,a new β-adrenoceptor antagonist and vasodilator antihypertensive drug, inhibits superoxide release from human neutrophils [J]. Eur J Pharmacol, 1992,214: 277 -280.
8[8]Christopher TG, Lopez BL,Ma XL,et al. Effects of a hydroxylated metabolite of the β-adrenoceptor antagonist,carvedilol,on post-ischaemic splanchnic tissue injury [J]. Br J Pharmacol, 1998,123: 292 -298.
9[9]Abreu RMV ,Santos DJSL,Moreno AJM. Effects of Carvediol and its analog BM910228 on mitochondrial function and oxidative stress [ J ]. J Pharmacol Exp Therapeut ,2000,295:1022-1030.
10[10]Oliveira PJ,Marques MPM ,de Carvalho LAEB. Effects of Carvedilol on isolated heart mitochondria: Evidence for a protonophoretic mechanism [ J ]. Biochem Biophys Res Commun,2000,276:82-87.